Thick primary melanoma has a heterogeneous tumor biology: An institutional series

World Journal of Surgical Oncology

Volumn 9, Issue , 2011, Pages

  Meguerditchian, Ari Nareg ^a   Asubonteng, Kobby ^b   Young, Calvin ^c   Lema, Bethany ^c   Wilding, Gregory ^b   Kane III, John M ^d  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

ADJUVANT THERAPY; AGED; ARTICLE; CANCER LOCALIZATION; CANCER SURGERY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; OVERALL SURVIVAL; PROGNOSIS; TUMOR VOLUME; ADOLESCENT; ADULT; LYMPHADENECTOMY; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODE EXCISION; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY;

EID: 79953854865     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-9-40     Document Type: Article

References (32)

1. Linos E, et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009, 129(7):1666-74. 10.1038/jid.2008.423, 2866180, 19131946.
2. Coit D, Sauven P, Brennan M. Prognosis of thick cutaneous melanoma of the trunk and extremity. Arch Surg 1990, 125(3):322-6.
3. Balch CM, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19(16):3635-48.
4. Balch CM. Surgical controversies in melanoma. J Clin Oncol 1988, 6(2):392-3.
5. Balch CM. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol 1988, 6(1):163-72.
6. Balch CM, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996, 224(3):255-63. discussion 263-6, 10.1097/00000658-199609000-00002, 1235362, 8813254.
7. Cascinelli N, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998, 351(9105):793-6. 10.1016/S0140-6736(97)08260-3, 9519951.
8. Schneebaum S, et al. Cutaneous thick melanoma. Prognosis and treatment. Arch Surg 1987, 122(6):707-11.
9. Sim FH, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. Cancer 1978, 41(3):948-56. 10.1002/1097-0142(197803)41:3<948::AID-CNCR2820410324>3.0.CO;2-Z, 638981.
10. Cherpelis BS, et al. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J Am Acad Dermatol 2001, 44(5):762-6. 10.1067/mjd.2001.112346, 11312421.
11. Essner R, Morton DL. Does the tumor status of the regional lymph nodes really matter in melanoma?. Ann Surg Oncol 2001, 8(10):749-51. 10.1007/s10434-001-0749-2, 11776484.
12. Gershenwald JE, et al. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol 2000, 7(2):160-5. 10.1007/s10434-000-0160-4, 10761797.
13. Carlson GW, et al. Sentinel lymph node mapping for thick (>or = 4-mm) melanoma: should we be doing it?. Ann Surg Oncol 2003, 10(4):408-15. 10.1245/ASO.2003.03.055, 12734090.
14. Ferrone CR, et al. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol 2002, 9(7):637-45. 10.1007/BF02574479, 12167577.
15. Vermeeren L, et al. Thick melanoma: prognostic value of positive sentinel nodes. World J Surg 2009, 33(11):2464-8. 10.1007/s00268-009-0159-3, 19649757.
16. Cecchi R, et al. Sentinel lymph node biopsy in patients with thick (= 4 mm) melanoma: a single-centre experience. J Eur Acad Dermatol Venereol 2007, 21(6):758-61. 10.1111/j.1468-3083.2006.02072.x, 17567303.
17. Ascierto PA, Kirkwood JM. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 2008, 6:62. 10.1186/1479-5876-6-62, 2605741, 18954464.
18. Hancock BW, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004, 22(1):53-61. 10.1200/JCO.2004.03.185, 14665609.
19. Kirkwood JM, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000, 18(12):2444-58.
20. Kirkwood JM, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001, 19(9):2370-80.
21. Kirkwood JM, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14(1):7-17.
22. Balch CM, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27(36):6199-206. 10.1200/JCO.2009.23.4799, 2793035, 19917835.
23. Karakousis CP. Surgical procedures and lymphedema of the upper and lower extremity. J Surg Oncol 2006, 93(2):87-91. 10.1002/jso.20349, 16425311.
24. Coit DG. National Comprehensive Cancer Network Practice Guidelines in Oncology: Melanoma. 2010, [cited April 20th 2010]., http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf
25. Kim SH, et al. Prognosis of thick cutaneous melanoma. J Am Coll Surg 1999, 188(3):241-7. 10.1016/S1072-7515(98)00296-8, 10065812.
26. Balch CM, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19(16):3622-34.
27. Morton DL, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005, 242(3):302-11. discussion 311-3, 1357739, 16135917.
28. Morton DL, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006, 355(13):1307-17. 10.1056/NEJMoa060992, 17005948.
29. Morton DL, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992, 127(4):392-9.
30. McMasters KM, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol 2004, 86(4):212-23. 10.1002/jso.20084, 15221928.
31. Scoggins CR, et al. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. Arch Surg 145(7):622-7.
32. Gajdos C, et al. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?. Cancer 2009, 115(24):5752-60. 10.1002/cncr.24660, 19827151.